Timberlyne Therapeutics: Valuation, Funding & Investors
Timberlyne Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for autoimmune disorders. The company is advancing CM313, a monoclonal antibody targeting CD38, aimed at addressing diseases with high unmet medical needs. Formed through a partnership between Mountainfield Venture Partners and Keymed Biosciences, Timberlyne Therapeutics holds global development and commercial rights for CM313 outside of greater China.
Leadership & Board
Key Executives
- Co-Founder
- Christian Fougner
- Current Number of Employees
- 7
- Current LinkedIn Followers
- 3,163
Latest Estimated Valuation
- Total Amount Raised
- $180M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $180M
- Latest Funding Round
- Series A
Employee Trend
Timberlyne Therapeutics had 7 employees as of November 16, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Timberlyne Therapeutics had 3,163 followers as of November 16, 2026. The number of followers increased by 3 (0.09%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Jan 10, 2025 | Series A | $180.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Braidwell LP | Series A |
| Venrock Healthcare Capital Partners | Series A |
| Abingworth | Series A |
| Bain Capital Life Sciences | Series A |
| Boyu Capital | Series A |
| Lilly Asia Ventures | Series A |
| 3H Health Investment | Series A |
Similar Companies
A snapshot of private companies similar to Timberlyne Therapeutics, helping you discover and navigate related company profiles.








